Duodenal Chromogranin A Cell Density as a Biomarker for the Diagnosis of Irritable Bowel Syndrome by El-Salhy, Magdy et al.
Research Article
Duodenal Chromogranin A Cell Density as a Biomarker for the
Diagnosis of Irritable Bowel Syndrome
Magdy El-Salhy,1,2 Odd Helge Gilja,2,3 Doris Gundersen,4
Jan Gunnar Hatlebakk,2 and Trygve Hausken2,3
1 Section for Gastroenterology, Department of Medicine, Stord Hospital, P.O. Box 4000, 54 09 Stord, Norway
2 Section for Gastroenterology, Department of Clinical Medicine, University of Bergen, 5021 Bergen, Norway
3National Centre for Ultrasound in Gastroenterology, Department of Medicine, Haukeland University Hospital, 5021 Bergen, Norway
4Department of Research, Helse-Fonna, 5528 Haugesund, Norway
Correspondence should be addressed to Magdy El-Salhy; magdy.elsalhy@sklbb.no
Received 7 February 2014; Accepted 3 May 2014; Published 16 June 2014
Academic Editor: AndrewThillainayagam
Copyright © 2014 Magdy El-Salhy et al.This is an open access article distributed under the Creative CommonsAttribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background andAim. ChromograninA (CgA) is a commonmarker for endocrine cells.Thedensity of duodenal CgA cells is reduced
in patients with irritable bowel syndrome (IBS). Methods. The present study was undertaken to evaluate the density of duodenal
CgA as a biomarker for the diagnosis of IBS. Two hundred and three patients with IBS were recruited (180 females and 23 males;
mean age, 36 years; range, 18–66 years). The control group comprised 86 healthy subjects without gastrointestinal complaints (77
females and 9 males; mean age, 38 years; range, 18–67 years). Biopsy samples were taken from the duodenum during gastroscopy.
Sections from these biopsy samples were immunostained for CgA using the avidin-biotin complex (ABC)method. CgA cell density
was quantified by computerized image analysis. Results. The CgA cell density was lower in IBS-total and in all of the IBS subgroups
than in the controls. The sensitivity and specificity for a cutoff of <200 cells/mm2 were 86% and 95%, respectively. Conclusion. The
duodenal CgA cell density seems to be a good biomarker for the diagnosis of IBS. It is an inexpensive, simple, and easy-to-use
method that does not require sophisticated equipment or considerable experience.
1. Introduction
Irritable bowel syndrome (IBS) is a common gastrointesti-
nal disorder that is characterized by recurrent abdominal
pain/discomfort and altered bowel habits (ranging from
diarrhea to constipation) and abdominal bloating [1]. The
results of physical examinations, blood tests, and radiological
and endoscopic examinations are normal in IBS patients.
The diagnosis of IBS in clinical practice has therefore been a
diagnosis of exclusion, where an extensive battery of exami-
nations and tests is conducted to exclude organic diseases that
could be responsible for the patient’s symptoms [2–5]. Since
1978, several attempts have been made to achieve a positive
diagnosis based on symptom assessments similar to those
used in psychiatry [6–13]. In 1988, an international panel of
experts introduced symptom-based criteria for the diagnosis
of IBS, known as Rome I criteria, which were succeeded
by refinements in 1999 (Rome II criteria) and 2006 (Rome
III criteria). According to Rome III criteria, IBS patients
are divided into three subtypes based on their stool pattern:
patients with diarrhea as the predominant symptom (IBS-
D), with both diarrhea and constipation (IBS-M), and with
constipation as the predominant symptom (IBS-C).
The aims of Rome diagnostic criteria were to achieve a
positive diagnosis, avoid unnecessary tests and examinations,
and optimize treatment. Although more than 2 decades have
passed since the introduction of the Rome criteria, they are
not widely used in everyday clinical practice [3, 14, 15]. The
main reason that the Rome criteria have failed to achieve
their goals is the potential tomiss organic diseases thatmimic
IBS symptoms, but which have different pathophysiology
and treatments. Furthermore, they are not applicable in real,
everyday clinical practice [2, 3, 14, 15]. There is a consensus
among gastroenterologists that a diagnostic biomarker for
IBS is urgently needed [16–18].
The duodenum harbors a large number of endocrine
cells and comprises numerous endocrine cell types [19]. It
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Figure 1: CgA cell density expressed in relation to epithelial cells, measured (a) in ten randomly chosen fields, (b) as the number of cells per
microscopic field in ten randomly chosen fields, and (c) as the number of cells per microscopic field in five randomly chosen fields in tissue
samples taken from controls and IBS-total, IBS-D, IBS-M, and IBS-C patients. a𝑃 < 0.0001 versus control group.
has been reported that the populations of several duodenal
endocrine cell types are reduced in patients with IBS [20].
Chromogranin A (CgA) is a common marker for these
endocrine cells [21–23], and consequently it has been found
that CgA is reduced in these patients [24]. It has been
suggested that the duodenal CgA cell density could be used
in the diagnosis of IBS patients [24], with a sensitivity and
specificity of 91% and 89%, respectively [5]. However, these
results were based on 41 IBS patients that included only IBS-D
and IBS-C subtypes and 42 controls. Thus, the present study
was undertaken to test the effectiveness of duodenal CgA cell
density as a marker for the diagnosis of IBS using a large
cohort of IBS patients including all IBS subtypes and a large
number of healthy subjects as controls.
2. Material and Methods
2.1. Patients and Controls. Two hundred and three patients
who fulfilled Rome III criteria for the diagnosis of IBS [6,
7] were recruited from patients referred to Stord Hospital
during 2002–2011. These patients comprised 180 females and
23males with amean age of 36 years (range, 18–66 years).The
subtypes of IBS in these patients were distributed as follows:
80 with IBS-D, 47 with IBS-M, and 76 with IBS-C. All of the
patients had a long duration of IBS symptoms and a symptom
onset that was not associated with any gastrointestinal or
other infections. All patients underwent a complete physical
examination and were investigated using the following blood
tests: full blood count, electrolytes, inflammatory markers,
liver tests, and thyroid function tests. They also underwent
further colonoscopy with segmental biopsies to exclude
microscopic colitis.
The control group comprised 86 healthy subjects without
gastrointestinal complaints (77 females and 9 males; mean
age, 38 years; range, 18–67 years). Of these subjects, 59 were
healthy volunteers who had no gastrointestinal complaints
and were recruited via local announcements at Stord Hos-
pital, Haukelands University Hospital, and the University
of Bergen, as well as in local newspapers. Fifteen were
from the population of Stord city and 44 were students or
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Figure 2: Duodenal CgA-immunoreactive cells in (a) a control subject, (b) a patient with IBS-D, (c) a patient with IBS-M, and (d) a patient
with IBS-C.
hospital employees. Twenty-seven healthy subjects submitted
to gastroscopy because of health worries due to a relative
being diagnosed with cancer.
The study was performed in accordance with the Decla-
ration of Helsinki and was approved by the Regional Com-
mittee for Medical and Health Research Ethics West, Bergen,
Norway. All subjects provided oral and written consent to
participate.
2.2. Gastroscopy, Histopathology, and Immunohistochemistry.
Gastroscopy was performed on both the patients and the
controls after an overnight fast. During gastroscopy, four
biopsy samples were taken from the descending part of the
duodenum, distal to the papilla of Vateri. Two additional
biopsy samples were taken from the antrum and used for a
rapid urease test to identify the presence ofHelicobacter pylori
(HelicotecUT Plus, Strong Biotech, Taipei, Taiwan).
The biopsy samples were fixed overnight in 4% buffered
paraformaldehyde, embedded in paraffin, and sectioned
at a thickness of 5 𝜇m. The sections were stained with
hematoxylin-eosin and immunostained using the avidin-
biotin complex (ABC) with the VECTASTAIN ABC kit
(Vector Laboratories, Burlingame, CA, USA). The primary
antibody used was a monoclonal mouse antibody raised
against the N-terminal of purified CgA (code no. M869,
Dako, Glostrup, Denmark). The sections were hydrated and
then immersed in 0.01% hydrogen peroxide in PBS buffer
(pH 7.4) for 10min to inhibit endogenous peroxidase activity.
After washing in buffer, the sections were treated with
1% bovine serum albumin for 30min to block nonspecific
binding sites and then incubated with the primary anti-
body diluted to 1 : 500 at room temperature for 1 h. The
sections were washed in PBS buffer and incubated with
biotinylated swine anti-mouse IgGdiluted 1 : 200 for 30min
at room temperature. After washing the slides in PBS buffer,
the sections were incubated for 30min with avidin-biotin-
peroxidase complex diluted to 1 : 100 and then immersed in
3,3󸀠-diaminobenzidine peroxidase substrate (Vector labora-
tories), followed by counterstaining in hematoxylin [8].
2.3. Quantification of CgA Cells. The CgA cell density was
quantified by computerized image analysis and by counting
positive cells in a microscopic field. Measurements using
computerized image analysis were performed on a computer
linked to a microscope (BX 43, Olympus) equipped with a
digital camera (DP 26, Olympus).The number of immunore-
active cells and the area of the epithelial cells were measured.
The number of endocrine cells in each field was counted
manually by pointing and clicking the computer mouse, and
the area of the epithelium containing these cells was drawn
manually using the computer mouse. A ×40 objective was
used, for which each frame (field) on themonitor represented
a tissue area of 0.14mm2. CgA cells were measured in ten
randomly chosen fields.
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Figure 3: ROC analysis for CgA cell density as measured relative to the area of the epithelium in (a) IBS-total, (b) IBS-D, (c) IBS-M, and (d)
IBS-C.
CgA-positive cells were counted in ten and five randomly
chosen microscopic fields using a ×40 objective. Immunos-
tained sections from the IBS patients and controls were coded
andmixed, andmeasurements weremade by the same person
(M.E.), who was blind to the identity of the sections. The
data from the fields were tabulated, and the cell density of
the epithelium (in cells per square millimeter) and number
of cells per microscopic field were computed.
2.4. Statistical Analysis. Differences in gender and the inci-
dence ofH. pylori infection between the patients and controls
were tested by chi-square and Fisher’s exact tests, respectively.
Differences in the age profile were tested by the Mann-
Whitney nonparametric test. Differences between controls,
all IBS patients (IBS-total), IBS-D, IBS-M, and IBS-C patients
were tested using the Kruskal-Wallis nonparametric test with
Dunn’s posttest. The data are presented as mean ± SEM
values, and differences with 𝑃 < 0.05 were considered to be
statistically significant.
3. Results
3.1. Patients and Controls. The gender and age distributions
did not differ significantly between the patients and the
controls (𝑃 = 1.0 and 𝑃 = 0.6, resp.). H. pylori infection was
found in 12 of the patients and 8 of the control subjects (as
evidenced by both the urease test and by histopathological
examination), and its incidence did not differ between the
two groups (𝑃 = 0.6).
3.2. Gastroscopy, Histopathology, and Immunohistochemistry.
The endoscopic findings were normal in both the patients
and the controls, and histopathological examination of the
duodenum revealed normal histology in all cases. CgA-
immunoreactive cells were found mostly in the crypts of
the duodenum of both the patients and the controls and
were basket- or flask-shaped, sometimes with a long basal
cytoplasmic process.
3.3. Quantification of CgA Cells. Computerized image anal-
ysis yielded CgA cell densities of 446.1 ± 16.0, 89.5 ± 7.2,
76.7±9.6, 142.9±15.9, and 69.8±100.5 cells/mm2 for controls
and IBS-total, IBS-D, IBS-M, and IBS-C patients, respectively
(Figures 1 and 2).The Kruskal-Wallis test was significant (𝑃 <
0.001). Dunn’s posttest revealed that CgA cell density was
lower in IBS-total and all of the IBS-subgroups relative to the
controls (𝑃 < 0.0001 for all). Receiver operator curve (ROC)
analysis for CgA cell density in the duodenum revealed that
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Figure 4: ROC analysis for CgA cell density as measured in ten randomly chosen microscopic fields in (a) IBS-total, (b) IBS-D, (c) IBS-M,
and (d) IBS-C.
the sensitivity and specificity for a cutoff of <200 cells/mm2
were 86% and 95%, respectively, in IBS-total, 93% and 95% in
IBS-D, 72% and 95% in IBS-M, and 87% and 95% in IBS-C
(Figure 3).
The numbers of CgA cells in ten microscopic fields
were 13 ± 1.0, 4 ± 0.3, 4 ± 0.3, 5 ± 0.4, and 3 ± 0.3
cells/field for controls and IBS-total, IBS-D, IBS-M, and IBS-
C patients, respectively (Figures 1 and 2). The Kruskal-Wallis
test revealed a statistically significant difference between
the controls and the IBS-total, IBS-D, IBS-M, and IBS-C
patients (𝑃 < 0.0001 for all). According to Dunn’s multiple
comparison test, the number of CgA cells was significantly
lower in the IBS-total, IBS-D, IBS-M, and IBS-C patients than
in the controls (𝑃 < 0.0001 for all). ROC analysis showed
that the sensitivity and specificity for a cutoff of <6 cells/field
were 89% and 88%, respectively, in IBS-total, 84% and 88%
in IBS-D, 77% and 88% in IBS-M, and 92% and 88% in IBS-C
(Figure 4).
The numbers of CgA cells in five microscopic fields
were 13 ± 1.0, 4 ± 0.3, 4 ± 0.4, 6 ± 0.5, and 4 ± 0.4
cells/field for controls and IBS-total, IBS-D, IBS-M, and IBS-
C patients, respectively (Figures 1 and 2). The Kruskal-Wallis
test revealed a statistically significant difference between the
controls and the IBS-total, IBS-D, IBS-M, and IBS-C patients
(𝑃 < 0.001 for all). Dunn’s test showed that the number of
CgA cells was significantly lower in the IBS-total, IBS-D, IBS-
M, and IBS-C patients than in the controls (𝑃 < 0.0001 for
all). ROC analysis showed that the sensitivity and specificity
for a cutoff of <6 cells/field were 80% and 86%, respectively,
in IBS-total, 88% and 86% in IBS-D, 62% and 86% in IBS-M,
and 88% and 86% in IBS-C (Figure 5).
4. Discussion
Awide range of biomarkers that reflect a pathological state in
IBS has been considered for the diagnosis of IBS [15–18].This
has prompted evaluations of several tests and examinations
measuring gut motility, visceral hypersensitivity, autonomic
reactivity, mucosal inflammation, fecal proteases, gut flora,
serum antibodies, and food allergy [15–18]. Unfortunately,
none of these tests or examinations has been found to be
useful as a biomarker for IBS diagnosis.
The number of endocrine cells in the gastrointestinal
tract is the largest in the duodenum, followed by the rectum
[25]. Moreover, the duodenum contains the largest number
of gut endocrine cell types, namely, serotonin, secretin,
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Figure 5: ROC analysis for CgA cell density as measured in five randomly chosen microscopic fields in (a) IBS-total, (b) IBS-D, (c) IBS-M,
and (d) IBS-C.
cholecystokinin (CCK), gastric inhibitory polypeptide (GIP),
somatostatin, and motilin [20]. Of these, the densities of four
cell types were shown to be reduced in patients with IBS:
secretin, CCK, GIP, and somatostatin cells [8]. The reduction
in the densities of these cells may account for the reported
reduction in the density of duodenal CgA cells in IBS patients
[9]. The duodenal CgA cell density thus reflects structural
abnormality occurring in the duodenal endocrine cells of IBS
patients [26].
The present study showed that duodenal CgA cell density
is a biomarker with good sensitivity and specificity for the
diagnosis of IBS. The use of computerized image analysis
provided slightly improved sensitivity and specificity than
direct counting of cell numbers in microscopic fields. How-
ever, computerized image analysis requires equipment that
might not be available in small pathological laboratories.
Considering the small gain in sensitivity and specificity, direct
counting with the aid of a microscope is preferable, especially
in small laboratories. As counting of ten randomly chosen
fields has better sensitivity and specificity than counting in
five fields, the former should be used. The sensitivity of
this biomarker seems to be lower for the IBS-M subtype
than for the other IBS-C and IBS-D subtypes. The densities
of duodenal endocrine cells in patients with celiac disease
have been reported to be increased [10]. The densities of the
duodenal endocrine cells in other diseases/disorders such as
duodenitis, gastritis, inflammatory bowel diseases, duodenal
and stomach ulcers, and gastrointestinal malignancy are not
known. Thus, the present observations do not exclude the
possibility that the alteration in CgA cell density may occur
in such diseases/disorders. Further studies on these patients’
group are needed before reaching any definite conclusion.
Screening of IBS patients for celiac disease (CD) is now
widely accepted [27–37]. Thus, gastroscopy with duodenal
biopsies can be used instead of serology for excluding or
confirming aCDdiagnosis, and the same biopsies can be used
for the diagnosis of IBS. Gastroscopy is generally accepted by
patients and immunohistochemistry is a routine method in
all pathological laboratories. Manually counting CgA cells in
ten microscopic fields is not time consuming and does not
require sophisticated equipment or considerable experience.
Immunohistochemical staining for CgA is not expensive and
is performed commonly in pathology laboratories for the
diagnosis of endocrine tumors.
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